Understanding why some triple negative breast cancer patients resist treatment
Systems Approaches to Understanding Subpopulation Heterogeneity in Therapeutic Resistance
This study is looking into why some people with triple negative breast cancer don’t respond to chemotherapy, using new technology to track how their cancer cells behave and change, with the goal of finding better, more personalized treatment options for patients like you.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-10918100 on NIH RePORTER |
What this research studies
This research investigates the reasons behind treatment resistance in patients with triple negative breast cancer (TNBC). By utilizing advanced technology to track individual cancer cells and their responses to chemotherapy, the study aims to uncover the complex behaviors of tumor cells that contribute to resistance. Researchers will analyze gene expression changes in these cells and create mathematical models to better predict how different subpopulations of cancer cells respond to treatment over time. This approach seeks to provide a more personalized understanding of TNBC and improve treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are undergoing or have undergone chemotherapy.
Not a fit: Patients with other types of breast cancer or those who have not been diagnosed with breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple negative breast cancer by overcoming resistance to therapy.
How similar studies have performed: Other research has shown promise in using similar technologies to understand cancer heterogeneity and treatment responses, indicating a potential for success in this approach.
Where this research is happening
Austin, United States
- University of Texas at Austin — Austin, United States (Active)
Researchers
- Principal investigator: Brock, Amy — University of Texas at Austin
- Study coordinator: Brock, Amy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.